Immune checkpoint inhibitors work by blocking proteins on the surface of immune cells, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1), which can restrict the immune system from identifying and purging and attacking cancer cells [3]. This evidence concerns the gene PDCD1 and cancer.